

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email civil.rights@doh.wa.gov.

| CPT | Code Description | Start Date | End Date | Max Allowed |
|-------|---|------------|-----------|-------------|
| U0001 | CDC SARS-CoV-2 lab test | 4/1/2022 | 3/31/2023 | \$46.00 |
| U0002 | Non-CDC SARS-CoV-2 lab test | 4/1/2022 | 3/31/2023 | \$67.00 |
| U0003 | Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (Coronavirus disease [COVID-19]) | 4/1/2022 | 3/31/2023 | \$67.00 |
| 99441 | Telephone eval and management, unrelated to E/M service provided in previous 7 days nor leading to E/M service within next available appointment, 5-10 minutes | 4/1/2022 | 3/31/2023 | \$32.00 |
| 99442 | Telephone eval and management, unrelated to E/M service provided in previous 7 days nor leading to E/M service within next available appointment, 11-20 minutes | 4/1/2022 | 3/31/2023 | \$52.00 |
| 99443 | Telephone eval and management, unrelated to E/M service provided in previous 7 days nor leading to E/M service within next available appointment, 20+ minutes | 4/1/2022 | 3/31/2023 | \$76.00 |
| 99422 | Online digital evaluation and management service, for an established patient, 11-20 minutes over 7 cumulative days | 4/1/2022 | 3/31/2023 | \$52.00 |
| 99423 | Online digital evaluation and management service, for an established patient, 20+ minutes over 7 cumulative day | 4/1/2022 | 3/31/2023 | \$76.00 |
| G0467 | Office visit | 4/1/2022 | 3/31/2023 | \$180.00 |
| G2012 | Brief communication technology-based service, unrelated to E/M service provided in previous 7 days nor leading to E/M service within next available appointment | 4/1/2022 | 3/31/2023 | \$11.00 |
| Q3014 | Telehealth/telemedicine originating facility fee | 4/1/2022 | 3/31/2023 | \$32.00 |
| 36415 | Collection of venous blood by venipuncture | 4/1/2022 | 3/31/2023 | \$4.00 |
| 36416 | Collection of capillary blood specimen | 4/1/2022 | 3/31/2023 | \$4.00 |
| 80048 | Basic metabolic panel, calcium total | 4/1/2022 | 3/31/2023 | \$30.00 |
| 80053 | Comprehensive metabolic panel | 4/1/2022 | 3/31/2023 | \$73.00 |
| 80061 | Direct measurement of high density cholesterol | 4/1/2022 | 3/31/2023 | \$21.00 |
| 82670 | Assay of Estradiol | 4/1/2022 | 3/31/2023 | \$42.00 |
| 82040 | Measurement of albumin in plasma | 4/1/2022 | 3/31/2023 | \$8.00 |
| 83036 | Measurement of glycosylated hemoglobin (HbA1C) | 4/1/2022 | 3/31/2023 | \$15.00 |
| 84146 | Assay if prolactin | 4/1/2022 | 3/31/2023 | \$70.00 |
| 84270 | Sex hormone binding globulin – SHBG | 4/1/2022 | 3/31/2023 | \$137.00 |
| 84403 | Measurement of total testosterone | 4/1/2022 | 3/31/2023 | \$38.00 |
| 85027 | Automated complete blood cell count | 4/1/2022 | 3/31/2023 | \$10.00 |
| 86631 | Chlamydia antibody | 4/1/2022 | 3/31/2023 | \$18.00 |
| 86632 | Chlamydia amplified probe | 4/1/2022 | 3/31/2023 | \$19.00 |
| 87110 | Bacterial culture for Chlamydia | 4/1/2022 | 3/31/2023 | \$30.00 |
| 87270 | Chlamydia trachomatis antigen detection using immunofluorescent technique | 4/1/2022 | 3/31/2023 | \$18.00 |
| 87320 | Chlamydia trachomatis antigen detection using qualitative multiple step enzyme immunoassay technique | 4/1/2022 | 3/31/2023 | \$18.00 |
| 87490 | Chlamydia trachomatis detection by nucleic acid using direct probe technique | 4/1/2022 | 3/31/2023 | \$30.00 |
| 87491 | Chlamydia trachomatis detection by nucleic acid using amplified probe technique | 4/1/2022 | 3/31/2023 | \$54.00 |
| 87492 | Chlamydia trachomatis detection by nucleic acid quantification | 4/1/2022 | 3/31/2023 | \$54.00 |
| 87810 | Chlamydia trachomatis antigen detection by immunoassay with direct optical observation | 4/1/2022 | 3/31/2023 | \$18.00 |
| 87590 | Neisseria gonorrhoeae detection by nucleic acid using direct probe technique | 4/1/2022 | 3/31/2023 | \$30.00 |
| 87591 | Neisseria gonorrhoeae detection by nucleic acid using amplified probe technique | 4/1/2022 | 3/31/2023 | \$63.00 |
| 87592 | Neisseria gonorrhoeae quantification by nucleic acid | 4/1/2022 | 3/31/2023 | \$65.00 |
| 87593 | Infectious agent detection by nucleic acid (DNA or RNA); orthopoxvirus (eg, monkeypox virus, cowpox virus, vaccinia virus), amplified probe technique, each | 4/1/2022 | 3/31/2023 | \$51.31 |
| 87850 | Neisseria gonorrhoeae antigen detection by immunoassay with direct optical observation | 4/1/2022 | 3/31/2023 | \$18.00 |
| 80074 | Acute hepatitis panel | 4/1/2022 | 3/31/2023 | \$72.00 |
| 80076 | Hepatic function panel T | 4/1/2022 | 3/31/2023 | \$30.00 |
| 86692 | Assay for hepatitis delta agent antibody | 4/1/2022 | 3/31/2023 | \$26.00 |
| 86704 | Assay for total Hepatitis B core antibody (HBcAb) | 4/1/2022 | 3/31/2023 | \$18.00 |
| 86705 | Assay for Hepatitis B immunoglobulin M core antibody (HBcAb) | 4/1/2022 | 3/31/2023 | \$18.00 |
| 86706 | Assay for Hepatitis B surface antibody (HBsAb) | 4/1/2022 | 3/31/2023 | \$16.00 |
| 86707 | Assay for Hepatitis B antibody (HBeAb) | 4/1/2022 | 3/31/2023 | \$18.00 |
| 86708 | Assay for total Hepatitis A antibody (HAAb) | 4/1/2022 | 3/31/2023 | \$19.00 |
| 86709 | Assay for Hepatitis A immunoglobulin M antibody (HAAb) | 4/1/2022 | 3/31/2023 | \$17.00 |
| 87340 | Hepatitis B surface antigen (HBsAg) detection using qualitative multiple step enzyme immunoassay technique | 4/1/2022 | 3/31/2023 | \$16.00 |
| 87341 | Hepatitis B surface antigen (HBsAg) neutralization using qualitative multiple step enzyme immunoassay technique | 4/1/2022 | 3/31/2023 | \$16.00 |
| 87350 | Hepatitis B (HBeAg) detection using qualitative multiple step enzyme immunoassay technique | 4/1/2022 | 3/31/2023 | \$17.00 |

| CPT | Code Description | Start Date | End Date | Max Allowed |
|-------|---|------------|-----------|-------------|
| 87380 | Hepatitis delta agent antigen detection using qualitative multiple step enzyme immunoassay technique | 4/1/2022 | 3/31/2023 | \$25.00 |
| 87516 | Hepatitis B virus detection by nucleic acid using amplified probe technique | 4/1/2022 | 3/31/2023 | \$54.00 |
| 87517 | Hepatitis B virus quantification by nucleic acid | 4/1/2022 | 3/31/2023 | \$66.00 |
| 87520 | Hepatitis C virus detection by nucleic acid using direct probe technique | 4/1/2022 | 3/31/2023 | \$30.00 |
| 87521 | Hepatitis C virus detection by nucleic acid using amplified probe technique | 4/1/2022 | 3/31/2023 | \$54.00 |
| 87522 | Hepatitis C virus quantification by nucleic acid | 4/1/2022 | 3/31/2023 | \$65.00 |
| 87912 | Analysis of infectious agent genotype of Hepatitis B virus | 4/1/2022 | 3/31/2023 | \$391.00 |
| 86769 | Covid Antibody Testing measure of severe acute respiratory syndrome coronavirus 2 (Covid -19) antibody | 4/1/2022 | 3/31/2023 | \$55.00 |
| 86803 | Hepatitis C antibody titer | 4/1/2022 | 3/31/2023 | \$22.00 |
| 86804 | Confirmatory Hepatitis C antibody titer | 4/1/2022 | 3/31/2023 | \$24.00 |
| 87902 | Analysis of infectious agent genotype of Hepatitis C virus | 4/1/2022 | 3/31/2023 | \$391.00 |
| 90739 | Hepatitis B Vaccine - Adult Dosage (2 dose schedule) for intermuscular use | 4/1/2022 | 3/31/2023 | \$85.00 |
| 86694 | Herpes simplex antibody titer | 4/1/2022 | 3/31/2023 | \$20.00 |
| 86695 | Herpes simplex type 1 antibody titer | 4/1/2022 | 3/31/2023 | \$20.00 |
| 86696 | Herpes simplex type 2 antibody titer | 4/1/2022 | 3/31/2023 | \$30.00 |
| 86689 | Confirmatory assay for Human T cell leukemia I virus (HTLV-I) antibody (Western Blot) | 4/1/2022 | 3/31/2023 | \$36.00 |
| 86701 | Assay for Human immunodeficiency virus 1 (HIV-1) antibody | 4/1/2022 | 3/31/2023 | \$14.00 |
| 86702 | Assay for Human immunodeficiency virus 2 (HIV-2) antibody | 4/1/2022 | 3/31/2023 | \$21.00 |
| 86703 | Combined assay for (HIV-1) antibody and (HIV-2) antibody | 4/1/2022 | 3/31/2023 | \$21.00 |
| 87391 | Human immunodeficiency virus 2 antigen detection using qualitative multiple step enzyme immunoassay technique | 4/1/2022 | 3/31/2023 | \$27.00 |
| 87534 | Human immunodeficiency virus 1 detection by nucleic acid using direct probe technique | 4/1/2022 | 3/31/2023 | \$30.00 |
| 87535 | Human immunodeficiency virus 1 detection by nucleic acid using amplified probe technique | 4/1/2022 | 3/31/2023 | \$54.00 |
| 87536 | Human immunodeficiency virus 1 quantification by nucleic acid | 4/1/2022 | 3/31/2023 | \$129.00 |
| 87537 | Human immunodeficiency virus 2 detection by nucleic acid using direct probe technique | 4/1/2022 | 3/31/2023 | \$31.00 |
| 87538 | Human immunodeficiency virus 2 (HIV-2) detection by nucleic acid using amplifeid probe technique | 4/1/2022 | 3/31/2023 | \$54.00 |
| 87539 | Human immunodeficiency virus 2 (HIV-2) quantification by nucleic acid | 4/1/2022 | 3/31/2023 | \$66.00 |
| 87389 | HIV-1 antigens with HIV-1 and HIV-2 antibodies | 4/1/2022 | 3/31/2023 | \$37.00 |
| 87390 | Human immunodeficiency virus 1 antigen detection using qualitative multiple step enzyme immunoassay technique | 4/1/2022 | 3/31/2023 | \$27.00 |
| 87806 | Alere Determine HIV 1/2 Ag/Ab Combo | 4/1/2022 | 3/31/2023 | \$18.00 |
| G0432 | Infectious agent antibody detection by EIA, HIV-1 and/or HIV-2 screening | 4/1/2022 | 3/31/2023 | \$27.00 |
| G0433 | Infectious agent antibody detection by ELISA, HIV-1 and/or HIV-2 screening | 4/1/2022 | 3/31/2023 | \$27.00 |
| G0435 | Infectious agent antibody detection by rapid antibody test, HIV-1 and/or HIV-2 screening | 4/1/2022 | 3/31/2023 | \$27.00 |
| 87623 | Human Papillomavirus (HPV) detection by nucleic acid | 4/1/2022 | 3/31/2023 | \$83.00 |
| 87624 | Human Papillomavirus (HPV) detection by nucleic acid | 4/1/2022 | 3/31/2023 | \$62.00 |
| 87625 | Human Papillomavirus (HPV) type 16 and 18 detection by nucleic acid | 4/1/2022 | 3/31/2023 | \$62.00 |
| 82955 | Measurement of glucose-6-phosphate dehydrogenase (G6PD) | 4/1/2022 | 3/31/2023 | \$15.00 |
| 82960 | Screening for glucose-6-phosphate dehydrogenase (G6PD) | 4/1/2022 | 3/31/2023 | \$10.00 |
| 84100 | Measurement of inorganic phosphorus (phosphate) | 4/1/2022 | 3/31/2023 | \$8.00 |
| 84207 | Measurement of pyridoxal phosphate (Vitamin B-6) | 4/1/2022 | 3/31/2023 | \$28.00 |
| 86317 | Quantitative immunoassay for infectious agent antibody | 4/1/2022 | 3/31/2023 | \$22.00 |
| 87081 | Presumptive screening culture for pathogenic organism | 4/1/2022 | 3/31/2023 | \$10.00 |
| 87205 | Smear from primary source with Giemsa stain for bacteria | 4/1/2022 | 3/31/2023 | \$6.00 |
| 87210 | Wet mount smear for infectious agent from primary source | 4/1/2022 | 3/31/2023 | \$7.00 |
| 87800 | Infectious agent detection by nucleic acid using direct probe technique | 4/1/2022 | 3/31/2023 | \$61.00 |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinic breast examination | 4/1/2022 | 3/31/2023 | \$102.00 |
| Q0091 | Obtaining screen pap smear | 4/1/2022 | 3/31/2023 | \$109.00 |
| 81025 | Urine pregnancy test using visual color comparison method | 4/1/2022 | 3/31/2023 | \$6.00 |
| 84702 | Measurement of chorionic gonadotropin (hCG) | 4/1/2022 | 3/31/2023 | \$23.00 |
| 84703 | Qualitative analysis of chorionic gonadotropin (hCG) | 4/1/2022 | 3/31/2023 | \$13.00 |
| 80069 | Renal function panel | 4/1/2022 | 3/31/2023 | \$30.00 |
| 82565 | Measurement of creatinine in blood | 4/1/2022 | 3/31/2023 | \$8.00 |
| 82570 | Measurement of creatinine | 4/1/2022 | 3/31/2023 | \$8.00 |
| 82575 | Creatinine clearance test | 4/1/2022 | 3/31/2023 | \$15.00 |
| 86592 | Qualitative assay for non-treponemal antibody | 4/1/2022 | 3/31/2023 | \$7.00 |
| 86593 | Quantitative assay for non-treponemal antibody | 4/1/2022 | 3/31/2023 | \$7.00 |
| 86780 | Assay for Treponema pallidum antibody | 4/1/2022 | 3/31/2023 | \$20.00 |

| CPT | Code Description | Start Date | End Date | Max Allowed |
|-------|---|------------|-----------|-------------|
| 87660 | Trichomonas vaginal direct probe | 4/1/2022 | 3/31/2023 | \$30.00 |
| 87661 | Trichomonas vaginalis, amplified probe | 4/1/2022 | 3/31/2023 | \$30.00 |
| 81000 | Manual urinalysis using dip stick and microscopy of urine | 4/1/2022 | 3/31/2023 | \$5.00 |
| 81001 | Automated urinalysis using dip stick and microscopy of urine | 4/1/2022 | 3/31/2023 | \$5.00 |
| 81002 | Manual urinalysis using dip stick | 4/1/2022 | 3/31/2023 | \$4.00 |
| 81003 | Automated urinalysis using dip stick | 4/1/2022 | 3/31/2023 | \$4.00 |
| 81005 | Qualitative urinalysis | 4/1/2022 | 3/31/2023 | \$4.00 |
| 81007 | Screen for bacteriuria | 4/1/2022 | 3/31/2023 | \$4.00 |
| 81015 | Microscopy of urine | 4/1/2022 | 3/31/2023 | \$5.00 |
| 84156 | Measurement of total protein in urine | 4/1/2022 | 3/31/2023 | \$6.00 |
| 90471 | Intradermal administration of a combination toxoid | 4/1/2022 | 3/31/2023 | \$21.00 |
| 90472 | Intradermal administration of each additional combination toxoid | 4/1/2022 | 3/31/2023 | \$11.00 |
| 90473 | Immunization admin through intranasal or oral route, 1 vaccine | 4/1/2022 | 3/31/2023 | \$21.00 |
| 90474 | Immunization admin through intranasal or oral route, each additional vaccine | 4/1/2022 | 3/31/2023 | \$20.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4/1/2022 | 3/31/2023 | \$21.00 |
| 90698 | Diphtheria, tetanus toxoids, acellular pertussis, haemophilus influenza Type B, and poliovirus vaccine (DTaP-Hib-IPV) | 4/1/2022 | 3/31/2023 | \$66.00 |
| 90700 | Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTP) | 4/1/2022 | 3/31/2023 | \$28.00 |
| 90702 | Diphtheria and tetanus toxoids adsorbed (DT) | 4/1/2022 | 3/31/2023 | \$84.00 |
| 90714 | Preservative free tetanus and diphtheria adsorbed toxoids (Td) | 4/1/2022 | 3/31/2023 | \$30.00 |
| 90715 | Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) | 4/1/2022 | 3/31/2023 | \$43.00 |
| 90632 | Hepatitis A vaccine, adult dosage | 4/1/2022 | 3/31/2023 | \$67.00 |
| 90636 | Hepatitis A and Hepatitis B vaccine (Twinrix®) | 4/1/2022 | 3/31/2023 | \$122.00 |
| 90740 | Hepatitis B vaccine, dialysis or immunosuppressed patient dosage | 4/1/2022 | 3/31/2023 | \$161.00 |
| 90743 | Hepatitis B vaccine, adolescent (2 dose schedule) for intramuscular use | 4/1/2022 | 3/31/2023 | \$32.00 |
| 90744 | Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule) for intramuscular use | 4/1/2022 | 3/31/2023 | \$32.00 |
| 90746 | Hepatitis B vaccine, adult dosage (3 dose schedule) for intramuscular use | 4/1/2022 | 3/31/2023 | \$81.00 |
| 90747 | Hepatitis B vaccine, dialysis or immunosuppressed patient (4 dose schedule) for intramuscular use | 4/1/2022 | 3/31/2023 | \$161.00 |
| 90748 | Hepatitis B and Haemophilus influenzae type b vaccine (Hib-Hep B) | 4/1/2022 | 3/31/2023 | \$59.00 |
| G0010 | Administration of hepatitis B vaccine | 4/1/2022 | 3/31/2023 | \$8.00 |
| 90649 | Human Papillomavirus vaccine, types 6, 11, 16, 18, 3 dose schedule, intramuscular use (Gardasil®) | 4/1/2022 | 3/31/2023 | \$177.00 |
| 90650 | Human Papillomavirus vaccine, types 16, 18, 3 dose schedule, intramuscular use (Cervarix®) | 4/1/2022 | 3/31/2023 | \$160.00 |
| 90651 | Human Papillomavirus vaccine, types 6, 11, 16, 18, 31, 33, 45, 52, 58, 3 dose schedule, intramuscular use (Gardasil 9®) | 4/1/2022 | 3/31/2023 | \$174.00 |
| 90655 | Split virus, preservative-free influenza virus vaccine | 4/1/2022 | 3/31/2023 | \$23.00 |
| 90656 | Split virus, preservative-free influenza virus vaccine | 4/1/2022 | 3/31/2023 | \$19.00 |
| 90658 | Split virus influenza virus vaccine | 4/1/2022 | 3/31/2023 | \$10.00 |
| 90662 | Influenza vaccine | 4/1/2022 | 3/31/2023 | \$36.00 |
| 90673 | Live virus, trivalent preservative-free influenza virus vaccine | 4/1/2022 | 3/31/2023 | \$49.00 |
| 90674 | Influenza virus vaccine | 4/1/2022 | 3/31/2023 | \$30.00 |
| 90682 | Influenza virus vaccine, derived from recombinant DNA, HA protein only, preservative & antibiotic free | 4/1/2022 | 3/31/2023 | \$30.00 |
| 90686 | Split virus, preservative free influenza virus vaccine, quadrivalent, for intramuscular use | 4/1/2022 | 3/31/2023 | \$24.00 |
| 90688 | Influenza virus vaccine | 4/1/2022 | 3/31/2023 | \$25.00 |
| 90756 | Influenza virus vaccine, quadrivalent, for intramuscular | 4/1/2022 | 3/31/2023 | \$30.00 |
| G0008 | Administration of influenza virus vaccine | 4/1/2022 | 3/31/2023 | \$8.00 |
| Q2035 | Afluria vacc, 3 yrs & >, im | 4/1/2022 | 3/31/2023 | \$16.00 |
| Q2036 | Flulaval vacc, 3 yrs & >, im | 4/1/2022 | 3/31/2023 | \$12.00 |
| Q2037 | Fluvirin vacc, 3 yrs & >, im | 4/1/2022 | 3/31/2023 | \$20.00 |
| Q2038 | Fluzone vacc, 3 yrs & >, im | 4/1/2022 | 3/31/2023 | \$21.00 |
| Q2039 | Nos flu vacc, 3 yrs & >, im | 4/1/2022 | 3/31/2023 | \$15.00 |
| 90620 | Meningococcal recombinant lipoprotein vaccine, 2 dose schedule, for intramuscular use (MenB) | 4/1/2022 | 3/31/2023 | \$141.00 |
| 90621 | Meningococcal recombinant lipoprotein vaccine, 3 dose schedule, for intramuscular use (MenB) | 4/1/2022 | 3/31/2023 | \$141.00 |
| 90733 | Meningococcal vaccine for subcutaneous use | 4/1/2022 | 3/31/2023 | \$102.00 |
| 90734 | Meningococcal vaccine for intramuscular use (MenACWY) | 4/1/2022 | 3/31/2023 | \$94.00 |
| 90707 | Measles, mumps and rubeolla vaccine | 4/1/2022 | 3/31/2023 | \$71.00 |
| 90670 | Pneumococcal conjugate vaccine - 13-valent | 4/1/2022 | 3/31/2023 | \$207.00 |
| 90732 | Pneumococcal polysaccharide vaccine - 23-valent | 4/1/2022 | 3/31/2023 | \$105.00 |
| G0009 | Administration of pneumococcal vaccine | 4/1/2022 | 3/31/2023 | \$8.00 |

| CPT | Code Description | Start Date | End Date | Max Allowed |
|-------|--|------------|-----------|-------------|
| 90736 | Live zoster (Shingles) vaccine (Zostovax®) | 4/1/2022 | 3/31/2023 | \$236.00 |
| 90750 | Zoster (shingles) vaccine (Shingrix®) | 4/1/2022 | 3/31/2023 | \$236.00 |
| J0696 | Ceftriaxone sodium injection | 4/1/2022 | 3/31/2023 | \$2.00 |
| J0561 | Penicillin g benzathine inj | 4/1/2022 | 3/31/2023 | \$7.00 |
| 99001 | Special Handeling fee, test kit transfer from patient to office/laboratory | 4/1/2022 | 3/31/2023 | \$30.00 |
| 99201 | Level 1 outpatient visit for evaluation and management of new patient with minor problem 10 minutes or less | 4/1/2022 | 3/31/2023 | \$52.00 |
| 99202 | Level 2 outpatient visit for evaluation of new patient with problem of low to moderate severity 20 minutes | 4/1/2022 | 3/31/2023 | \$90.00 |
| 99203 | Level 3 outpatient visit for evaluation new patient with problem of moderate severity, 30 minutes | 4/1/2022 | 3/31/2023 | \$127.00 |
| 99204 | Level 4 outpatient visit for new patient with problem of moderate to high severity, 45 minutes | 4/1/2022 | 3/31/2023 | \$193.00 |
| 99205 | Level 5 outpatient visit for new patient with problem of moderate to high severity, 60 minutes | 4/1/2022 | 3/31/2023 | \$241.00 |
| 99211 | Level 1 outpatient visit for evaluation of established patient with minimal presenting problem, typical time less than 5 minutes | 4/1/2022 | 3/31/2023 | \$24.00 |
| 99212 | Level 2 outpatient visit for evaluation a established patient 10 minutes or less | 4/1/2022 | 3/31/2023 | \$53.00 |
| 99213 | Level 3 outpatient visit for established patient with problem of low to moderate severity 15 minutes | 4/1/2022 | 3/31/2023 | \$86.00 |
| 99214 | Level 4 outpatient visit for established patient with problem of moderate to high severity 25 minutes | 4/1/2022 | 3/31/2023 | \$127.00 |
| 99215 | Level 5 outpatient visit for evaluation established patient 40 minutes | 4/1/2022 | 3/31/2023 | \$172.00 |
| 99243 | Level 3 outpatient consultation for established patient 40 minutes | 4/1/2022 | 3/31/2023 | \$101.00 |
| 99401 | Preventive medicine counseling and risk factor reduction intervention for individual - approximately 15 minutes | 4/1/2022 | 3/31/2023 | \$30.00 |
| 99402 | Preventitive medicine counseling and risk factor reduction, 30 minutes | 4/1/2022 | 3/31/2023 | \$26.00 |
| 99403 | Preventive medicine counseling and risk factor reduction, 45 minutes | 4/1/2022 | 3/31/2023 | \$128.00 |
| 99404 | Preventive medicine counseling and risk factor reduction, 60 minutes | 4/1/2022 | 3/31/2023 | \$52.00 |
| G0442 | Annual alcohol misuse screening, 15 minutes | 4/1/2022 | 3/31/2023 | \$22.00 |
| G0443 | Brief face to face behavioral counseling for alcohol misuse, 15 minutes | 4/1/2022 | 3/31/2023 | \$32.00 |
| G0445 | Semiannual high intensity behavioral counseling to prevent STIs, individual face to face, 20-30 minutes | 4/1/2022 | 3/31/2023 | \$35.00 |
| G0463 | Hospital Outpatient Clinic Visit | 4/1/2022 | 3/31/2023 | \$125.00 |
| H0031 | Mental health assessment, by non-physician | 4/1/2022 | 3/31/2023 | \$96.00 |